Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2825358 | 0.75 | — | — | |
| SCHEMBL7131721 | 0.73 | CYP1A2 (0.35) | CYP1A2CYP2D6 | |
| SCHEMBL28364614 | 0.73 | GABRR1 (0.33) | CYP1A2CYP2D6ARG1ARG2 | |
| SCHEMBL9720660 | 0.72 | — | — | |
| SCHEMBL442847 | 0.72 | — | — | |
| SCHEMBL740307 | 0.72 | — | — | |
| SCHEMBL8473650 | 0.70 | TSHR (0.38) | CYP2D6TP53ALDH1A1TSHRFFAR3 | |
| SCHEMBL31288699 | 0.70 | SLC7A5 (0.34) | CYP1A2CYP2D6SLC7A5 | |
| SCHEMBL30273061 | 0.70 | GABRR1 (0.35) | CYP1A2CYP2D6ARG1ARG2ALDH1A1 | |
| SCHEMBL2330301 | 0.70 | NOS1 (0.33) | CYP1A2CYP2D6ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025109220-A1 | METHOD OF PURIFICATION OF ECTOINE AND COMPOSITION THEREOF | METABOLIC EXPLORER (FR) | 2025-05-30 | — | — | WO | claimed |
| CN-110461321-A | Composition containing N-acetyl diaminobutyric acid | BITOP AG | 2019-11-15 | — | — | CN | claimed |
| EP-3558287-A2 | N-ACETYLDIAMINOBUTYRIC ACID-CONTAINING COMPOSITION | Bitop AG (DE) | 2019-10-30 | — | — | EP | claimed |
| CN-104583232-A | Glucagon analogs exhibiting GIP receptor activity | UNIV INDIANA RES & TECH CORP | 2015-04-29 | — | — | CN | claimed |
| WO-2025109220-A1 | METHOD OF PURIFICATION OF ECTOINE AND COMPOSITION THEREOF | METABOLIC EXPLORER (FR) | 2025-05-30 | — | — | WO | disclosed |
| WO-2024223833-A1 | GENETICALLY MODIFIED MICROORGANISM FOR PRODUCING ECTOINE | C-LECTA GMBH (DE) | 2024-10-31 | — | — | WO | disclosed |
| CN-118667736-A | Recombinant escherichia coli for synthesizing hydroxytetrahydropyrimidine and application thereof | 江南大学 | 2024-09-20 | — | — | CN | disclosed |
| CN-110381917-B | Use of compatible solutes | 默克专利股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-114806974-B | Salmonella strain and application thereof | 中国科学院微生物研究所 | 2023-08-08 | — | — | CN | disclosed |
| CN-115461470-A | Method for separating nuclei and cells from tissue | 10X基因组学有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-114806974-A | Halomonas strain and application thereof | 中国科学院微生物研究所 | 2022-07-29 | — | — | CN | disclosed |
| EP-2970511-B1 | INSULIN-INCRETIN CONJUGATES | UNIV INDIANA RES & TECH CORP (US) | 2020-09-30 | — | — | EP | disclosed |
| WO-2009010367-A2 | AGENTS COMPRISING AN ANTI-IRRITANT ACTIVE SUBSTANCE | HENKEL AG & CO. KGAA (DE) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008017734-A1 | POLYMYXIN DERIVATIVES AND USES THEREOF | NORTHERN ANTIBIOTICS OY (FI) | 2008-02-14 | — | — | WO | disclosed |
| CN-1303991-C | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivative process for preparing the same | WARNER LAMBERT CO (US) | 2007-03-14 | — | — | CN | disclosed |
| WO-2006029712-A1 | POLYALKOXYLATED DIAMINOBENZENES FOR USE AS DEVELOPERS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-03-23 | — | — | WO | disclosed |
| US-20050201955-A1 | Use of compatible solutes for inhibiting the release of ceramides | SUSONITY Commercial GmbH (DE) | 2005-09-15 | — | — | US | disclosed |
| CN-1301155-A | Stable pharmaceutical formulation of gamma-aminobutyric acid derivatives and process for preparing the same | WARNER LAMBERT CO (US) | 2001-06-27 | — | — | CN | disclosed |
| EP-0749429-A1 | 3,5-DISUBSTITUTED AND 3,5,6-TRISUBSTITUTED 2-ISOXAZOLINES AND ISOXAZOLES, PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-12-27 | — | — | EP | disclosed |
| WO-1995024397-A1 | 3,5-DISUBSTITUTED AND 3,5,6-TRISUBSTITUTED 2-ISOXAZOLINES AND ISOXAZOLES, PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050201955-A1 | Use of compatible solutes for inhibiting the release of ceramides | CERT1, UGCG, CERS2 | CYP1A2 4709/4885CYP2D6 4827/4885SLC7A5 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.